Genentech Inc.'s Avastin received FDA approval as a first-line treatment in metastatic colorectal cancer. With the company saying it will launch the product into the eager arms of patients and doctors within three days and sales expectations high, the drug seems bound for biotechnology folklore. (BioWorld Today)

VIENNA, Austria - The Cordia-EuropaBio Convention 2003 brought together industry representatives from throughout Europe last week. With companies and investors expected from Europe's far reaches, rumors were it would attract about 2,500 attendees.